Myocardial Viability: From Proof of Concept to Clinical Practice
Ischaemic left ventricular (LV) dysfunction can arise from myocardial stunning, hibernation, or necrosis. Imaging modalities have become front-line methods in the assessment of viable myocardial tissue, with the aim to stratify patients into optimal treatment pathways. Initial studies, although favo...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2016/1020818 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551537999609856 |
|---|---|
| author | Aditya Bhat Gary C. H. Gan Timothy C. Tan Chijen Hsu Alan Robert Denniss |
| author_facet | Aditya Bhat Gary C. H. Gan Timothy C. Tan Chijen Hsu Alan Robert Denniss |
| author_sort | Aditya Bhat |
| collection | DOAJ |
| description | Ischaemic left ventricular (LV) dysfunction can arise from myocardial stunning, hibernation, or necrosis. Imaging modalities have become front-line methods in the assessment of viable myocardial tissue, with the aim to stratify patients into optimal treatment pathways. Initial studies, although favorable, lacked sufficient power and sample size to provide conclusive outcomes of viability assessment. Recent trials, including the STICH and HEART studies, have failed to confer prognostic benefits of revascularisation therapy over standard medical management in ischaemic cardiomyopathy. In lieu of these recent findings, assessment of myocardial viability therefore should not be the sole factor for therapy choice. Optimization of medical therapy is paramount, and physicians should feel comfortable in deferring coronary revascularisation in patients with coronary artery disease with reduced LV systolic function. Newer trials are currently underway and will hopefully provide a more complete understanding of the pathos and management of ischaemic cardiomyopathy. |
| format | Article |
| id | doaj-art-67eff2ad5c0b41d58087c27317008a30 |
| institution | Kabale University |
| issn | 2090-8016 2090-0597 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-67eff2ad5c0b41d58087c27317008a302025-02-03T06:01:17ZengWileyCardiology Research and Practice2090-80162090-05972016-01-01201610.1155/2016/10208181020818Myocardial Viability: From Proof of Concept to Clinical PracticeAditya Bhat0Gary C. H. Gan1Timothy C. Tan2Chijen Hsu3Alan Robert Denniss4Department of Cardiology, Blacktown Hospital, Blacktown Road, Blacktown NSW 2148, AustraliaDepartment of Cardiology, Blacktown Hospital, Blacktown Road, Blacktown NSW 2148, AustraliaDepartment of Cardiology, Blacktown Hospital, Blacktown Road, Blacktown NSW 2148, AustraliaDepartment of Cardiology, Blacktown Hospital, Blacktown Road, Blacktown NSW 2148, AustraliaDepartment of Cardiology, Blacktown Hospital, Blacktown Road, Blacktown NSW 2148, AustraliaIschaemic left ventricular (LV) dysfunction can arise from myocardial stunning, hibernation, or necrosis. Imaging modalities have become front-line methods in the assessment of viable myocardial tissue, with the aim to stratify patients into optimal treatment pathways. Initial studies, although favorable, lacked sufficient power and sample size to provide conclusive outcomes of viability assessment. Recent trials, including the STICH and HEART studies, have failed to confer prognostic benefits of revascularisation therapy over standard medical management in ischaemic cardiomyopathy. In lieu of these recent findings, assessment of myocardial viability therefore should not be the sole factor for therapy choice. Optimization of medical therapy is paramount, and physicians should feel comfortable in deferring coronary revascularisation in patients with coronary artery disease with reduced LV systolic function. Newer trials are currently underway and will hopefully provide a more complete understanding of the pathos and management of ischaemic cardiomyopathy.http://dx.doi.org/10.1155/2016/1020818 |
| spellingShingle | Aditya Bhat Gary C. H. Gan Timothy C. Tan Chijen Hsu Alan Robert Denniss Myocardial Viability: From Proof of Concept to Clinical Practice Cardiology Research and Practice |
| title | Myocardial Viability: From Proof of Concept to Clinical Practice |
| title_full | Myocardial Viability: From Proof of Concept to Clinical Practice |
| title_fullStr | Myocardial Viability: From Proof of Concept to Clinical Practice |
| title_full_unstemmed | Myocardial Viability: From Proof of Concept to Clinical Practice |
| title_short | Myocardial Viability: From Proof of Concept to Clinical Practice |
| title_sort | myocardial viability from proof of concept to clinical practice |
| url | http://dx.doi.org/10.1155/2016/1020818 |
| work_keys_str_mv | AT adityabhat myocardialviabilityfromproofofconcepttoclinicalpractice AT garychgan myocardialviabilityfromproofofconcepttoclinicalpractice AT timothyctan myocardialviabilityfromproofofconcepttoclinicalpractice AT chijenhsu myocardialviabilityfromproofofconcepttoclinicalpractice AT alanrobertdenniss myocardialviabilityfromproofofconcepttoclinicalpractice |